MarketPulse
V

$VTGN

23 articles found
0 positive
23 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

VTGN Investors Face March 16 Deadline in Securities Fraud Class Action

Securities class action filed against VTGN alleges misleading statements about fasedienol drug and PALISADE-3 trial. Investors must act by March 16, 2026 deadline.
VTGNPhase 3 clinical trialsecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Vistagen Hit with Securities Fraud Lawsuit Over Fasedienol Trial Data

Class action lawsuit filed against $VTGN alleges securities fraud over misleading statements about fasedienol drug candidate and PALISADE-3 clinical trial data.
VTGNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Vistagen Investors Pursue Securities Fraud Claims Over Misleading Drug Trial Statements

Schall Law Firm seeks Vistagen investors in class action over alleged false statements regarding fasedienol drug candidate's Phase 3 trial prospects.
VTGNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Investors Face March 16 Deadline in Securities Lawsuit Over Trial Disclosures

Rosen Law Firm urges Vistagen investors to join securities class action by March 16, 2026, over alleged misstatements regarding fasedienol and clinical trials.
VTGNsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Vistagen Faces Class Action Over Alleged Misstatements on Fasedienol Trial Data

Class action lawsuit filed against $VTGN alleging securities fraud over fasedienol drug trial statements and concealed adverse clinical data.
VTGNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Securities Lawsuit: Investors Face March 16 Deadline in PALISADE-3 Trial Dispute

Vistagen faces securities fraud lawsuit over fasedienol trial misstatements. Affected investors have until March 16, 2026 deadline to seek lead plaintiff status or secure counsel.
VTGNPhase 3 clinical trialsecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Vistagen Faces Class Action Lawsuit Over Failed Trial, Stock Crashes 80%

Class action lawsuit filed against Vistagen Therapeutics after Phase 3 trial failure causes 80% stock plunge. Investors have until March 16, 2026 deadline.
VTGNclass action lawsuitmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Therapeutics Faces Securities Class Action Over Drug Trial Disclosure Allegations

Rosen Law Firm announces March 16, 2026 deadline for investors to join securities class action against Vistagen Therapeutics ($VTGN) over alleged misleading statements regarding fasedienol drug trial.
VTGNsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Faces Securities Lawsuit Over Fasedienol Drug Claims

Vistagen Therapeutics faces securities lawsuit over alleged fasedienol misstatements. Investors who purchased VTGN stock April 2024-December 2025 may be eligible for compensation; lead plaintiff deadline is March 16, 2026.
VTGNPhase 3 clinical trialsecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Holzer & Holzer, Llc

Shareholder Lawsuits Filed Against CoreWeave, Bath & Body Works, and Vistagen; Lead Plaintiff Deadlines Set

Shareholder lawsuits filed against CoreWeave, Bath & Body Works, and Vistagen for alleged disclosure violations. Lead plaintiff deadlines set for March 2026.
CRWVBBWIVTGNinvestor losseslead plaintiff
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Vistagen Investors Face Class Action Deadline Following Failed Phase 3 Trial

Vistagen faces class action lawsuit after Phase 3 trial failure for anxiety drug. Stock plunged 80%. Investors must act by March 16, 2026 deadline.
VTGNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Holzer & Holzer, Llc

Vistagen Therapeutics Investors Face March 16 Deadline in Securities Litigation

Vistagen Therapeutics shareholders must file for lead plaintiff status by March 16, 2026 in securities fraud lawsuit alleging false statements and undisclosed risks.
KDVRNSVTGNinvestor lossesshareholder lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Investors Face March Deadline in Securities Litigation Over Trial Disclosures

Vistagen faces securities lawsuit over misleading trial disclosures. Investors must nominate lead plaintiff by March 16, 2026 deadline.
VTGNsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Lawsuit Filed Against Vistagen Over Alleged Misstatements on Drug Trial

Class action lawsuit filed against Vistagen Therapeutics for alleged false statements regarding drug trial data. Investors who purchased securities April 2024-December 2025 may be eligible.
VTGNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Class Action Cases Launched Against PomDoctor, Vistagen Over Alleged Securities Violations

Class action lawsuits filed against PomDoctor and Vistagen Therapeutics alleging securities violations. Vistagen's stock fell 80% after failed clinical trial results.
VTGNPOMsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Investors Face March Deadline in Securities Litigation Over Trial Disclosures

Vistagen investors face March 16, 2026 deadline in securities lawsuit alleging false statements about drug trials and clinical data that misled shareholders.
VTGNsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Class Action Deadline Looms for uniQure Investors Amid FDA Approval Claims

uniQure faces securities class action over allegedly misleading FDA approval claims and timeline delays. Investors must act before April 13, 2026 deadline.
QUREVTGNLUinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

Vistagen Faces Securities Fraud Lawsuit Over Failed Phase 3 Trial Results

Vistagen faces class action lawsuit for securities fraud after its Phase 3 trial failed, causing stock to plummet 80%. Investors allege misleading statements about trial progress.
VTGNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Pomerantz Launches Class Action Against Vistagen Following Failed Trial, Sets March Deadline

Pomerantz launches class action against Vistagen after failed clinical trial caused 80% stock drop. March 16, 2026 deadline for investors to join lawsuit.
SDMVTGNCLEUFsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Class Action Filed Against China Liberal Education Over Alleged Securities Fraud

Class action lawsuit filed against China Liberal Education for alleged securities fraud involving fraudulent social media advisors that artificially inflated stock prices before collapse.
BBWIVTGNCLEUFsecurities fraudclass action lawsuit